An update on the use of Atripla® in the treatment of HIV in the United States
Michael A Horberg1, Daniel B Klein21HIV Interregional Initiative, Kaiser Permanente, Oakland, California, USA; 2Department of Infectious Diseases, Kaiser Permanente Hayward Medical Center, Hayward, California, USAAbstract: Atripla® (Gilead Sciences Inc, Foster City, CA, USA and Bristol-M...
Guardado en:
Autores principales: | Michael A Horberg, Daniel B Klein |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1db7236ac07249adbbb8302f8067db94 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients
por: Putcharoen O, et al.
Publicado: (2013) -
Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
por: Eva Poveda, et al.
Publicado: (2010) -
Effect of once-daily FDC treatment era on initiation of cART
por: David M Mosen, et al.
Publicado: (2010) -
Evaluating the McDonald's business model for HIV prevention among truckers to improve program coverage and service utilization in India, 2004–2010
por: Tirumalasetti Rao V, et al.
Publicado: (2013) -
The use of preexposure treatments for HIV prophylaxis
por: Majid A, et al.
Publicado: (2012)